Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that has gained significant clinical importance due to its potent, rapid, and sustained suppression of gastric acid secretion. Unlike conventional proton pump inhibitors, vonoprazan is chemically stable in acidic environments and does not require acid activation, resulting in improved therapeutic outcomes in acid-related gastrointestinal disorders. With the increasing use of vonoprazan in pharmaceutical formulations, the development and validation of reliable analytical methods for its quantitative estimation are essential to ensure quality, safety, and efficacy. This review focuses on the physicochemical properties, pharmacological profile, and analytical techniques employed for the estimation of vonoprazan in bulk drug and pharmaceutical dosage forms. Emphasis is given to chromatographic methods such as LC–MS/MS and HPLC, as well as UV spectrophotometric techniques, highlighting their principles, advantages, and applications in quality control and pharmacokinetic studies.
Kaveri* et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: